Logo
Logo


ISSN: 0300-9041
ISSNe: 2594-2034


Indizada en: SciELO, Índice Médico Latinoamericano, LILACS, Medline
Editada por la Federación Mexicana de Colegios de Obstetricia, y Ginecologia AC
Fundada por la Asociación Mexicana de Ginecología y Obstetricia en 1945
 

INFORMACIÓN EXCLUSIVA PARA LOS PROFESIONALES DE LA SALUD


Periodicidad: continua
Abreviatura: Ginecol Obstet Mex
ISSN: 0300-9041
ISSNe: 2594-2034
Indizada en: Scimago, Índice Médico Latinoamericano, Lilacs, Medline, Science Citation Index, Ulrich, Ebsco.

Anticonceptivos hormonales en pacientes con sangrado uterino disfuncional

Hormonals contraceptives in dysfunctional uterine bleeding patients.

Ginecol Obstet Mex. 2020;88(Supl 1):S163-S177.

https://doi.org/10.24245/gom.v88iSupl1.3855

Imelda Hernández-Marín, Cintia Mariel Villegas-Rodríguez, Cuauhtémoc Celis-González


Corrrespondencia:

Imelda Hernández Marín
marime64@hotmail.com

Debe citarse como:

Hernández-Marín I, Villegas-Rodríguez CM, Celis-González C. Anticonceptivos hormonales en pacientes con sangrado uterino disfuncional. Ginecol Obstet Mex. 2020;88(Supl 1):S163-S177. https://doi.org/10.24245/gom.v88iSupl1.3855

Resumen

El sangrado uterino anormal es una alteración común que afecta, incluso, a 30% de las mujeres en edad reproductiva y tiene repercusión significativa en su calidad de vida: física, social, emocional, sexual y financiera. El costo de la prestación de servicios de salud es equivalentemente elevado. El sangrado uterino anormal  en mujeres en edad reproductiva se define como la hemorragia del cuerpo uterino, que es anormal en cuanto a duración, volumen, frecuencia y regularidad, y que ha persistido durante seis meses. La Federación Internacional de Ginecología y Obstetricia (FIGO) publicó en 2007 el primer programa estandarizado para la nomenclatura y los parámetros de la hemorragia uterina normal (definida por los percentiles 5-95 sobre la base de los estudios epidemiológicos disponibles a gran escala). Este sistema fue diseñado para crear términos y definiciones de sangrado uterino normal en los años reproductivos, que minimicen la ambigüedad para su evaluación. Hoy día se utiliza el sistema publicado en el año 2011. El sangrado uterino disfuncional es un diagnóstico de exclusión. Establecer el tratamiento es complicado y variable, según el caso. Aunque la histerectomía fue la primera opción en la década de 1960, el tratamiento médico ha evolucionado recientemente. El objetivo de este estudio es revisar la función de los anticonceptivos en las nuevas modalidades de tratamiento de la hemorragia uterina disfuncional.

PALABRAS CLAVE: Sangrado uterino anormal; sangrado uterino disfuncional, calidad de vida; anticonceptivos hormonales combinados.

Abstract

Abnormal uterine bleeding is a common disorder affecting 30% of women in reproductive age and has a significant impact on their quality of life: physical, social, emotional, sexual and financial. The cost of providing health services is equivalently high. Abnormal uterine bleeding in women of reproductive age is defined as bleeding from the uterine body, which is abnormal in terms of duration, volume, frequency and regularity, and which has persisted for six months. The International Federation of Gynecology and Obstetrics (FIGO) published in 2007 the first standardized program for the nomenclature and parameters of normal uterine bleeding (defined by the 5-95 percentiles based on epidemiological studies available on a large scale). This system was designed to create terms and definitions of normal uterine bleeding in the reproductive years that minimize ambiguity for evaluation. Nowadays, the system published in the year 2011 is used. Dysfunctional uterine bleeding is a diagnosis of exclusion. Establishing the treatment is complicated and variable, depending on the case. Although hysterectomy was the first option in the 1960s, medical treatment has evolved recently. The aim of this study is to review the role of contraceptives in the new forms of treatment of dysfunctional uterine bleeding.

KEYWORDS: Abnormal uterine bleeding; Dysfunctional uterine bleeding; Quality of life; Combined hormonal contraceptives.

    1. Bradley LD, et al. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol 2016;214(1):31-44. https://doi.org/10.1016/j.ajog.2015.07.044
    2. Whitaker L, et al. Abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol 2016;34:54-65. https://doi.org/10.1016/j.bpobgyn.2015.11.012
    3. Hapangama DK, et al. Pathophysiology of heavy menstrual bleeding. Womens Health 2016;12(1):3-13. https://doi.org/10.2217/whe.15.81
    4. Busby G. Menstrual dysfunction. Obstet Gynaecol Reprod Med 2016;26(5):149-154. https://doi.org/10.1016/j.ogrm.2016.02.003
    5. Corbacioglu A. The management of dysfunctional uterine bleeding. Intechopen 2011. https://www.intechopen.com/books/update-on-mechanisms-of-hormone-action-focus-on-metabolism-growth-and-reproduction/the-management-of-dysfunctional-uterine-bleeding
    6. Töz E, et al. Comparison of classic terminology with the FIGO PALM-COEIN system for classification of the underlying causes of abnormal uterine bleeding. In J Gynaecol Obstet 2016;133(3):325-328. https://doi.org/10.1016/j.ijgo.2015.09.033
    7. Bandi ND, et al. Utility of the PALM-COEIN classification of abnormal uterine bleeding for Indian gynecologists. Int J Gynaecol Obstet 2016;133(2):196-198. https://doi.org/0.1016/j.ijgo.2015.09.030
    8. Munro MG. Practical aspects of the two FIGO systems for management of abnormal uterine bleeding in the reproductive years. Best Pract Res CLin Obstet Gynaecol 2017;40:3-22. https://doi.org/10.1016/j.bpobgyn.2016.09.011
    9. Gupta J, et al. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013;368(2):128-137. https://www.nejm.org/doi/10.1056/NEJMoa1204724
    10. Motta T, et al. Dysfunctional uterine bleeding. Good Pract Pediatr Adol Gynecol 2017;99-115. https://doi.org/10.1007/978-3-319-57162-1_6
    11. Creatsas M, et al. Dysfunctional uterine bleeding during adolescence. Front Gynecol Endocrinol 2014;1:9-14. https://doi.org/10.1007/978-3-319-03494-2_2
    12. James AH. Heavy menstrual bleeding: work-up and management. Hematology Am Soc Hematol Educ Program 2016;2016(1):236-242. https://doi.org/10.1182/asheducation-2016.1.236
    13. Smith RP. The physiology of menstruation. In: Dysmenorrhea and Menorrhagia. Springer, Cham 2018:1-17. https://doi.org/10.1007/978-3-319-71964-1_1
    14. Maybin JA. Menstrual physiology: implications for endometrial pathology and beyond. Hum Reprod Update 2015;21(6):748-761. https://doi.org/10.1093/humupd/dmv038
    15. Benetti-Pinto CL. Abnormal uterine bleeding. Rev Bras Ginecol Obstet 2017;39(7):358-368. http://dx.doi.org/10.1055/s-0037-1603807
    16. Bahamondes L, et al. Recent advances in managing and understanding menstrual disorders. F1000Prime Pep 2015;7:33. http://f1000.com/prime/reports/m/7/33
    17. Sriprasert I, et al. Heavy menstrual bleeding diagnosis and medical management. Contracept Reprod Med 2017;2(1):20. https://doi.org/10.1186/s40834-017-0047-4
    18. Jensen JT, et al. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol 2011;117:777-87. https://doi.org/10.1097/AOG.0b013e3182118ac3.
    19. Nappi RE, et al. Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature. Int J Womens Health 2014:6:711. https://doi.org/10.2147/IJWH.S65481
    20. Polis RL, et al. Treatment options for the adolescent patient experiencing abnormal uterine bleeding. Curr Treatm Options Pediatr 2016;2(3):184-195. https://doi.org/10.1007/s40746-016-0054-8
    21. Friedlander E, et al. Therapeutic options for unscheduled bleeding associated with long-acting reversible contraception. Obst Gynecol Clin North Am 2015;42(4):593-603. https://doi.org/10.1016/j.ogc.2015.07.004
    22. Dhamangaonkar PC, et al. Levonorgestrel intrauterine system (Mirena): An emerging tool for conservative treatment of abnormal uterine bleeding. J Midlife Health 2015;6(1):26. https://doi.org/10.4103/0976-7800.153615
    23. Gopimohan R, et al. A clinical study assessing the efficacy of a new variant of the levonorgestrel intrauterine system for abnormal uterine bleeding. Int J Gynecol Obstet 2015;129(2):114-117. https://doi.org/10.1016/j.ijgo.2014.11.023.
    24. Fraser IS, et al. Health-related quality of life and economic burden of abnormal uterine bleeding. Exp Rev Obstet Gynecol 2009;4(2):179-189. https://doi.org/10.1586/17474108.4.2.179

Comentarios